Quality of life in heart failure: A review

S. Adebayo, T. Olunuga, A. Durodola, O. Ogah
{"title":"Quality of life in heart failure: A review","authors":"S. Adebayo, T. Olunuga, A. Durodola, O. Ogah","doi":"10.4103/0189-7969.201914","DOIUrl":null,"url":null,"abstract":"Heart failure (HF) is a major cause of morbidity and mortality worldwide. HF severity and mortality can be predicted by measurement of quality of life (QOL). Generic and disease-specific instruments for measurement of QOL have been shown to be effective in clinical settings and in research. QOL compares favorably with traditional calibrators of HF severity such as New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), 6-min walk test (6MWT), and B-type natriuretic peptide levels. QOL measurement using domains such as social interaction, emotion, environmental interaction, sexual activity, and demographic characteristics, among others, can be used effectively in resource-limited environments, as well as adjunct to echocardiography and BNP. Lower QOL predicts early and more frequent HF hospitalization, depression, higher NYHA class, poor 6MWT, lower estimated glomerular filtration rate, and lower LVEF. Older age, lower socioeconomic status, longer duration of HF, and comorbidities correspond to lower QOL scores. Clinical trials incorporating QOL as primary and/or secondary end-point show improved QOL with the use of angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, beta blockers, device therapies, such as implantable cardiac defibrillator, and exercise-based rehabilitation. The aim of this paper is to review information on QOL in HF.","PeriodicalId":228906,"journal":{"name":"Nigerian Journal of Cardiology","volume":"72 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nigerian Journal of Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/0189-7969.201914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 20

Abstract

Heart failure (HF) is a major cause of morbidity and mortality worldwide. HF severity and mortality can be predicted by measurement of quality of life (QOL). Generic and disease-specific instruments for measurement of QOL have been shown to be effective in clinical settings and in research. QOL compares favorably with traditional calibrators of HF severity such as New York Heart Association (NYHA) class, left ventricular ejection fraction (LVEF), 6-min walk test (6MWT), and B-type natriuretic peptide levels. QOL measurement using domains such as social interaction, emotion, environmental interaction, sexual activity, and demographic characteristics, among others, can be used effectively in resource-limited environments, as well as adjunct to echocardiography and BNP. Lower QOL predicts early and more frequent HF hospitalization, depression, higher NYHA class, poor 6MWT, lower estimated glomerular filtration rate, and lower LVEF. Older age, lower socioeconomic status, longer duration of HF, and comorbidities correspond to lower QOL scores. Clinical trials incorporating QOL as primary and/or secondary end-point show improved QOL with the use of angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, beta blockers, device therapies, such as implantable cardiac defibrillator, and exercise-based rehabilitation. The aim of this paper is to review information on QOL in HF.
心力衰竭患者的生活质量:综述
心力衰竭(HF)是全世界发病率和死亡率的主要原因。通过测量生活质量(QOL)可以预测HF的严重程度和死亡率。用于测量生活质量的通用和特定疾病的仪器已被证明在临床环境和研究中是有效的。与纽约心脏协会(NYHA)分级、左室射血分数(LVEF)、6分钟步行试验(6MWT)和b型利钠肽水平等传统的心衰严重程度校准器相比,QOL具有优势。使用诸如社会互动、情感、环境互动、性活动和人口特征等领域来测量生活质量,可以在资源有限的环境中有效地使用,也可以辅助超声心动图和BNP。较低的生活质量预示着早期和更频繁的HF住院、抑郁、较高的NYHA分级、较差的6MWT、较低的肾小球滤过率和较低的LVEF。年龄越大、社会经济地位越低、心衰持续时间越长以及合并症与较低的生活质量评分相对应。将生活质量作为主要和/或次要终点的临床试验表明,使用血管紧张素受体阻滞剂、血管紧张素转换酶抑制剂、受体阻滞剂、植入式心脏除颤器等器械治疗和基于运动的康复治疗可以改善生活质量。本文旨在对心衰患者的生活质量进行综述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信